Sep 14, 2026 | Press Releases
Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b TrialKing of Prussia, Pennsylvania–(Newsfile Corp. – September 14, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA...
Sep 11, 2026 | Press Releases
Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762King of Prussia, Pennsylvania–(Newsfile Corp. – September 11, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company...
Aug 11, 2026 | Press Releases
PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.King of Prussia, Pennsylvania–(Newsfile Corp. – August 11, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a...
Aug 6, 2026 | Press Releases
Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcementsKing of Prussia, Pennsylvania–(Newsfile Corp. – August...
Jul 22, 2026 | Press Releases
Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – July 22, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics...
Jul 22, 2026 | Press Releases
Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – July 22, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics...